Mounjaro vs Wegovy: Which GLP-1 Is Right for You?
Reviewed by Dr. James Okafor, PharmDPharmD
Mounjaro vs Wegovy: Head-to-Head Comparison
Mounjaro (tirzepatide) and Wegovy (semaglutide) are two of the most effective GLP-1 medications available. They work differently, have different FDA-approved indications, and produce meaningfully different weight loss outcomes.
This comparison covers what the clinical data actually shows, how costs differ, and which drug fits which situation.
Quick Summary
| Mounjaro | Wegovy | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Mechanism | GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA approved for | Type 2 diabetes | Obesity/overweight (weight management) |
| Dosing | Weekly injection | Weekly injection |
| Dose range | 2.5–15mg weekly | 0.25–2.4mg weekly |
| Average weight loss | ~20.2% at 72 weeks | ~13.7% at 72 weeks |
| With insurance | ~$25/mo (T2D) | ~$0–25/mo (obesity coverage) |
| Self-pay (telehealth) | ~$1,000+/mo | ~$250–349/mo |
| Obesity indication | Zepbound (same molecule) | Wegovy |
What does the evidence show for Mounjaro vs Wegovy weight loss?
SURMOUNT-5 showed tirzepatide producing 20.2% average body weight loss versus 13.7% for semaglutide at 72 weeks — a gap of roughly 6–7 percentage points. This is the strongest available direct comparison between the two drugs.
SURMOUNT-5 was the first randomized controlled trial directly comparing tirzepatide to semaglutide for weight management. Results at 72 weeks:
| Drug | Average Weight Loss | ≥20% Body Weight Loss | ≥25% Body Weight Loss |
|---|---|---|---|
| Tirzepatide 15mg | ~20.2% | ~48% | ~31% |
| Semaglutide 2.4mg | ~13.7% | ~26% | ~13% |
Tirzepatide's advantage is substantial — roughly 6–7 percentage points more average weight loss. The dual GIP+GLP-1 mechanism drives stronger appetite suppression and metabolic effects.
In practical terms: For a 250-pound person, tirzepatide means ~50 lbs average vs ~34 lbs average on Wegovy.
Why Mounjaro and Wegovy Are Not Directly Interchangeable
Approved indications matter for insurance:
- Mounjaro is FDA-approved for type 2 diabetes. Insurance covers it for T2D, not obesity.
- Wegovy is FDA-approved for obesity/overweight with comorbidity. Insurance (where available) covers it for weight management.
- Zepbound is the tirzepatide product approved for weight management — same molecule as Mounjaro, different indication.
If you have T2D + obesity, Mounjaro is both clinically appropriate and likely covered by insurance. If you have obesity without T2D, Wegovy or Zepbound are the appropriate branded options. Some providers prescribe Mounjaro off-label for weight management, but coverage is unlikely without a T2D diagnosis.
How do Mounjaro and Wegovy compare on price?
The cash-pay cost gap is significant. Wegovy is dramatically more affordable out-of-pocket than Mounjaro at retail because Mounjaro has no dedicated cash-pay program — tirzepatide for weight loss is accessible at lower cost through Zepbound's LillyDirect program instead.
With Commercial Insurance
| Drug | Situation | Estimated Monthly Cost |
|---|---|---|
| Mounjaro | T2D, with insurance + Lilly savings card | ~$25/mo |
| Mounjaro | T2D, Medicare | ~$50/mo (Medicare negotiated price) |
| Wegovy | Obesity, with insurance + NovoCare savings card | $0–$25/mo |
| Wegovy | Obesity, Medicare Bridge (effective Jul 1, 2026) | ~$50/mo |
Without Insurance (Self-Pay)
| Drug | Self-Pay Option | Monthly Cost |
|---|---|---|
| Mounjaro | Retail pharmacy | ~$1,069–$1,112/mo |
| Mounjaro | No dedicated cash-pay program | ~$1,000+/mo |
| Wegovy | Branded (through telehealth: Ro, Hims) | ~$250–349/mo |
| Wegovy pill (25mg oral) | Branded (Ro, Hims) | ~$199/mo |
| Zepbound (tirzepatide obesity) | LillyDirect single-dose vials | $299–449/mo |
Side Effects Comparison
Both drugs share the GLP-1 drug class side effect profile. Tirzepatide adds GIP receptor effects but the clinical side effect experience is broadly similar.
| Side Effect | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Nausea | 12–18% | 16–44% |
| Vomiting | 6–9% | 5–24% |
| Diarrhea | 12–17% | 9–30% |
| Constipation | 6–11% | 3–24% |
| Injection site reaction | 3–7% | 3–5% |
Key takeaway: GI side effects are common with both drugs during titration, but rates are broadly similar. Tirzepatide may have a slightly more favorable GI profile at equivalent weight-loss efficacy levels — a meaningful distinction for patients who struggled with semaglutide's GI effects.
Shared contraindications (both drugs):
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Active pancreatitis
Which should you choose: Mounjaro or Wegovy?
When patients ask "Mounjaro vs Wegovy which is better," the practical answer often comes down to diagnosis and insurance — not pure efficacy.
Mounjaro may be the better fit if:
- You have type 2 diabetes AND obesity
- Your insurance covers Mounjaro for T2D
- You've tried semaglutide and found it less effective than expected
- You want the highest average weight loss and have coverage
Wegovy may be the better fit if:
- You have obesity/overweight without T2D
- Your commercial insurance covers Wegovy for weight management
- You are paying cash — Wegovy is substantially more affordable self-pay
- You prefer the established long-term safety data (semaglutide's SELECT cardiovascular trial)
Consider Zepbound instead of Mounjaro if:
- You want tirzepatide for obesity without T2D
- Zepbound's LillyDirect program ($299/mo starter) is relevant to your cost situation
Frequently Asked Questions
Is Mounjaro or Wegovy better for weight loss? In the SURMOUNT-5 head-to-head trial, tirzepatide (Mounjaro/Zepbound) produced ~20.2% average weight loss vs ~13.7% for semaglutide (Wegovy) at 72 weeks. Tirzepatide's dual GIP+GLP-1 mechanism is the primary driver. That said, Mounjaro is approved for T2D only — for weight loss without diabetes, the tirzepatide comparison should be Zepbound vs. Wegovy.
Is Mounjaro worth it vs Wegovy if I'm paying out of pocket? At retail prices, Mounjaro (~$1,069/mo) doesn't have a cash-pay program for the T2D indication. Wegovy at ~$250–349/mo through telehealth is much more accessible. For tirzepatide without insurance, Zepbound via LillyDirect at $299/mo is the practical option.
Can I switch from Wegovy to Mounjaro? Yes, with your prescriber's guidance. Switching from semaglutide to tirzepatide is common when patients want to try the dual-mechanism drug or haven't achieved their goal weight on semaglutide. The transition typically involves starting tirzepatide at the lowest dose regardless of your current semaglutide dose level.
Does Wegovy have heart benefits that Mounjaro doesn't? Semaglutide has an FDA-approved cardiovascular risk reduction indication based on the SELECT trial (20% reduction in MACE in adults with obesity/overweight and established cardiovascular disease). Tirzepatide does not yet have an equivalent approved indication, though trials are underway.
What is the cheapest way to get tirzepatide online? LillyDirect offers Zepbound (tirzepatide, obesity indication) starting at $299/mo for self-pay patients. Some telehealth platforms also offer compounded tirzepatide at $278–$349/mo, though compounding supply is under ongoing FDA enforcement pressure.
What is the bottom line on Mounjaro vs Wegovy?
Tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Wegovy) in head-to-head data — ~20% vs ~14%. The dual mechanism is the driver.
But the clinical comparison is only part of the decision. Cost, insurance coverage, and FDA-approved indication determine whether you're comparing Mounjaro or Zepbound to Wegovy in your specific situation.
For most patients without T2D: Wegovy vs. Zepbound is the right comparison, not Wegovy vs. Mounjaro.
Related guides:
Where to Get These Medications
Compare providers offering GLP-1 medications.
Related Guides
Does Medicare Cover Wegovy? Complete 2026 Coverage Guide
Medicare Part D is expanding Wegovy coverage for weight loss via the Bridge program (scheduled July 1, 2026). Here's what's expected, what you'll pay, how to qualify, and how to navigate prior authorization.
Read guide →Hims Wegovy: Everything About the Novo Nordisk Deal, Pricing & Transition
Complete guide to Hims' transition from compounded semaglutide to branded Wegovy through the Novo Nordisk partnership — pricing, timeline, what current patients should do.
Read guide →Mounjaro Cost Without Insurance in 2026: All Your Options
Mounjaro costs $1,069–$1,112/month at retail without any coverage — and unlike Zepbound, there is no $299/month LillyDirect cash-pay option. If you have commercial insurance, the Lilly Savings Card brings that to $25/month. Medicare patients pay ~$50/month in 2026. Here is every option explained.
Read guide →Mounjaro Cost Without Insurance in 2026: Real Prices + Savings Options
Mounjaro's retail cash price is $1,069–$1,112/month without insurance — and unlike Zepbound, there is no flat-rate manufacturer cash-pay program. With commercial insurance and the Lilly Savings Card, cost drops to $25/month. Medicare patients pay ~$50/month in 2026.
Read guide →